Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18952423 | VISCOELASTIC HYDROGEL REGULATION OF ORGANOID PATTERNING AND VASCULARIZATION | November 2024 | August 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18583342 | ONCOLYTIC ADENOVIRUSES ARMED WITH HETEROLOGOUS GENES | February 2024 | February 2026 | Allow | 24 | 0 | 1 | Yes | No |
| 18540309 | TARGETED GENE INSERTION FOR IMPROVED IMMUNE CELLS THERAPY | December 2023 | April 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18560712 | Mesenchymal Stem Cells for Use in the Treatment of Skin Defects | November 2023 | March 2026 | Allow | 28 | 0 | 0 | Yes | No |
| 18480890 | METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION | October 2023 | January 2025 | Allow | 15 | 0 | 1 | No | No |
| 18033756 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE DISEASE WITH IPSC-INDUCED HUMAN SKELETAL MUSCLE STEM CELLS | April 2023 | March 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18156887 | Pocket Engineering of HLA Alleles for Treating Autoimmunity | January 2023 | June 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 17998752 | COMPOSITIONS, SYSTEMS, AND METHODS FOR GENERATING GENE-EDITED CELLS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17954512 | A CRISPR-Cas9-inhibiting polypeptide | September 2022 | March 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 17819480 | METHOD OF TREATMENT OF CANCER OR TUMOUR | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17904082 | ORGAN EXTRACELLULAR MATRIX-DERIVED SCAFFOLD FOR CULTURE AND TRANSPLANTATION OF ORGANOID AND METHOD OF PREPARING THE SAME | August 2022 | October 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17830218 | NR4A-DEFICIENT CELLS EXPRESSING C-JUN AND USES THEREOF | June 2022 | March 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17751266 | CHIMERIC ANTIGEN RECEPTOR | May 2022 | February 2025 | Allow | 33 | 3 | 1 | Yes | No |
| 17741438 | HLA ENGINEERING METHODS AND COMPOSITIONS FOR TREATMENT OF AUTOIMMUNITY | May 2022 | December 2024 | Allow | 31 | 1 | 1 | No | No |
| 17773755 | GENERATION OF CD38 KNOCK-OUT PRIMARY AND EXPANDED HUMAN NK CELLS | May 2022 | February 2026 | Abandon | 45 | 2 | 0 | No | No |
| 17724038 | CATIONIC DENDRIMERS FOR THE CULTURE OF ADHERENT CELLS | April 2022 | December 2024 | Allow | 31 | 2 | 1 | No | No |
| 17714873 | GENE TRANSFER VECTORS AND METHODS OF ENGINEERING CELLS | April 2022 | January 2026 | Abandon | 45 | 4 | 1 | No | No |
| 17709150 | GENETICALLY MODIFIED MICE COMPRISING HUMANIZED CELLULAR IMMUNE SYSTEM COMPONENTS WITH IMPROVED DIVERSITY OF TCRB REPERTOIRE | March 2022 | April 2025 | Allow | 36 | 2 | 1 | Yes | No |
| 17763412 | TISSUE ENGINEERED 3D MODELS FOR CANCER METASTASIS | March 2022 | August 2025 | Allow | 40 | 1 | 1 | No | No |
| 17679247 | CO-CULTURE APPARATUS, CO-CULTURE SYSTEM, AND CO-CULTURE METHOD | February 2022 | October 2024 | Allow | 32 | 2 | 0 | No | No |
| 17421133 | CELLULAR IMMUNOTHERAPY IN COMBINATION WITH GEMCITABINE | January 2022 | March 2026 | Allow | 56 | 1 | 1 | Yes | No |
| 17585365 | MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES | January 2022 | August 2025 | Allow | 42 | 2 | 0 | No | No |
| 17629948 | SYSTEMS AND METHODS FOR EVALUATING NK CELLS | January 2022 | January 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17628483 | CHIMERIC ANTIGEN RECEPTORS FOR DIRECT AND INDIRECT TARGETING OF FIBRONECTIN-POSITIVE TUMORS | January 2022 | October 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17578059 | Methods and Compositions for Selective Generation of Dopaminergic Precursors | January 2022 | October 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17627193 | GENETICALLY ENGINEERED IMMUNE EFFECTOR CELLS COMPRISING R-PHYCOERYTHRIN-TARGETING RECEPTOR CONJUGATED CHIMERIC ANTIGEN RECEPTOR | January 2022 | December 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17597580 | CHIMERIC ANTIGEN RECEPTORS CONTAINING GLYPICAN 2 BINDING DOMAINS | January 2022 | February 2026 | Allow | 49 | 2 | 0 | No | No |
| 17573371 | IN VITRO LIVER ORGANOIDS AND MINI-BILE DUCT MODELS OF BILIARY ARTRESIA AND APPLICATIONS THEREOF | January 2022 | July 2025 | Abandon | 43 | 3 | 1 | No | No |
| 17626345 | METHOD FOR PRODUCING CELL POPULATION CONTAINING CAR-EXPRESSING IMMUNE CELLS | January 2022 | February 2026 | Allow | 50 | 3 | 0 | Yes | No |
| 17597269 | METHOD OF DETERMINING OR INFLUENCING THE CHONDROGENIC POTENTIAL OF MESENCHYMAL STROMAL CELLS | December 2021 | December 2025 | Allow | 47 | 1 | 1 | No | No |
| 17563599 | CD8 POLYPEPTIDES, COMPOSITIONS, AND METHODS OF USING THEREOF | December 2021 | October 2024 | Allow | 33 | 1 | 1 | No | No |
| 17619789 | ALL-IN ONE VECTOR FOR CAR AND THERAPEUTIC EFFECTOR MOLECULE | December 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17456374 | METHODS FOR CULTURING IMMUNE CELLS | November 2021 | March 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17609250 | BCMA-TARGETING ENGINEERED IMMUNE CELL AND USE THEREOF | November 2021 | November 2025 | Allow | 48 | 1 | 1 | No | No |
| 17607816 | CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS | October 2021 | December 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17505627 | AUTOMATED CLOSED SYSTEM FOR CELL THERAPY MANUFACTURING | October 2021 | May 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17603539 | MÜLLERIAN INHIBITING SUBSTANCE TYPE 2 RECEPTOR (MISIIR)-SPECIFIC CAR T CELLS FOR THE TREATMENT OF OVARIAN CANCER AND OTHER GYNECOLOGIC MALIGNANCIES | October 2021 | October 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17598619 | GENERATION OF CHIMERIC ANTIGEN RECEPTOR (CAR)-PRIMARY NK CELLS FOR CANCER IMMUNOTHERAPY USING A COMBINATION OF CAS9/RNP AND AAV VIRUSES | September 2021 | February 2026 | Allow | 53 | 2 | 1 | Yes | No |
| 17442387 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING ALZHEIMERS DISEASE | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17480404 | GENETICALLY MODIFIED CELLS, TISSUES, AND ORGANS FOR TREATING DISEASE | September 2021 | July 2025 | Allow | 46 | 1 | 0 | No | No |
| 17478271 | NERVE BUNDLE AND PRODUCTION METHOD OF NERVE BUNDLE | September 2021 | February 2026 | Allow | 53 | 3 | 1 | No | No |
| 17436872 | SILICIFIED IMMUNOGENIC CELLS, METHODS OF MAKING, AND METHODS OF USING | September 2021 | October 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 17404826 | MODIFIED MESENCHYMAL STEM CELL CULTURE MEDIUM, BONE MARROW MESENCHYMAL STEM CELLS AND CULTURE METHODS AND USE THEREOF | August 2021 | June 2025 | Abandon | 45 | 4 | 1 | No | No |
| 17392620 | Combination Treatment Of Induced Pluripotent Stem Cells Using Interleukins | August 2021 | October 2025 | Abandon | 51 | 4 | 1 | No | No |
| 17418103 | Human Vgamma9Vdelta2T Cell Proliferation Culture Method and Culture Medium | June 2021 | December 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17312581 | COMPOSITIONS AND METHODS FOR IMMUNOSUPPRESSION | June 2021 | April 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17344654 | Methods of Preserving Cells for Space Exploration and Compositions Related Thereto | June 2021 | November 2024 | Abandon | 41 | 2 | 1 | Yes | No |
| 17312744 | CHIMERIC ANTIGEN RECEPTORS TARGETING CD79B AND CD19 | June 2021 | September 2025 | Allow | 51 | 1 | 1 | Yes | No |
| 17312120 | DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES | June 2021 | August 2025 | Allow | 51 | 1 | 1 | Yes | No |
| 17335808 | INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF | June 2021 | June 2025 | Abandon | 48 | 4 | 1 | No | No |
| 17332532 | COMPOSITIONS AND METHODS FOR OBTAINING VASCULARIZED HUMAN INTESTINAL ORGANOID TISSUE, AND RELATED USES THEREOF | May 2021 | September 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17309315 | SUICIDE GENE | May 2021 | March 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17245368 | CONTROLLING FREEZE-DRYING OF A HYDROGEL | April 2021 | March 2025 | Allow | 46 | 4 | 1 | Yes | No |
| 17245445 | METHOD FOR FREEZE-DRYING A HYDROGEL COMPOSITION AND A FREEZE-DRIED HYDROGEL COMPOSITION | April 2021 | March 2025 | Allow | 47 | 4 | 1 | Yes | No |
| 17241708 | THREE DIMENSIONAL HUMAN BRAIN TUMOR MODELS | April 2021 | June 2025 | Allow | 49 | 3 | 1 | Yes | No |
| 17280467 | CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) AND CD22 CAR COMBINATION THERAPIES | March 2021 | February 2025 | Abandon | 47 | 2 | 2 | No | No |
| 17272865 | T CELL MODIFICATION | March 2021 | March 2025 | Abandon | 49 | 3 | 1 | Yes | No |
| 17271430 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | February 2021 | January 2026 | Allow | 59 | 2 | 2 | No | No |
| 17256527 | MITOCHONDRIAL AUGMENTATION THERAPY OF OCULAR DISEASES | December 2020 | November 2024 | Allow | 46 | 1 | 0 | No | No |
| 17253553 | GENE DRIVE TARGETING FEMALE DOUBLESEX SPLICING IN ARTHROPODS | December 2020 | September 2025 | Abandon | 57 | 1 | 1 | No | No |
| 17253046 | CELL | December 2020 | January 2025 | Abandon | 49 | 0 | 1 | No | No |
| 16972202 | ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING PROTEIN L FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY | December 2020 | February 2026 | Allow | 60 | 3 | 1 | Yes | No |
| 17051461 | THREE-DIMENSIONAL CULTURE METHOD, THREE-DIMENSIONAL CULTURE STRUCTURE, AND THREE-DIMENSIONAL CULTURE STRUCTURE MANUFACTURING METHOD | October 2020 | November 2024 | Abandon | 48 | 2 | 1 | Yes | No |
| 17050741 | MYOSIN 15 PROMOTERS AND USES THEREOF | October 2020 | September 2024 | Allow | 47 | 0 | 1 | Yes | No |
| 17049362 | METHOD FOR PRODUCING PANCREATIC BETA CELLS | October 2020 | September 2025 | Allow | 59 | 2 | 1 | Yes | No |
| 17047990 | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY | October 2020 | June 2025 | Allow | 56 | 1 | 1 | Yes | No |
| 17066378 | METHOD OF ASSESSING WOUND HEALING POTENCY OF A MESENCHYMAL STEM POPULATION AND RELATED METHODS OF SELECTING MESENCHYMAL STEM CELLS AND IDENTIFYING TISSUE AS STARTING MATERIAL FOR PRODUCING A MESENCHYMAL STEM CELL POPULATION | October 2020 | June 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 16763875 | METHOD FOR INDUCING URETERIC BUD-LIKE TISSUE | October 2020 | October 2025 | Allow | 60 | 1 | 2 | No | No |
| 17044843 | METHODS OF ASSESSING AND TREATING AUTISM SPECTRUM DISORDERS USING HUMAN UMBILICAL CORD TISSUE-DERIVED MESENCHYMAL STROMAL CELLS | October 2020 | August 2025 | Allow | 59 | 2 | 1 | Yes | No |
| 17026101 | VIRAL AND NON-VIRAL NANOPLASMID VECTORS WITH IMPROVED PRODUCTION | September 2020 | January 2026 | Allow | 60 | 3 | 1 | No | No |
| 15733619 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | September 2020 | July 2025 | Allow | 58 | 4 | 1 | Yes | No |
| 16979378 | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | September 2020 | March 2026 | Abandon | 60 | 3 | 1 | No | Yes |
| 16978800 | RECOMBINANT ADENO-ASSOCIATED VIRUSES ENCODING SERPIN PEPTIDES AND USES THEREOF | September 2020 | December 2024 | Allow | 51 | 2 | 1 | No | No |
| 16971890 | NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES | August 2020 | October 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16971215 | COMPOSITIONS FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION | August 2020 | October 2025 | Allow | 60 | 2 | 1 | No | Yes |
| 16965226 | DEVICE FOR PRODUCING GLOBULES OF ADIPOSE TISSUE | July 2020 | September 2024 | Allow | 50 | 2 | 0 | Yes | No |
| 16957896 | CELL POPULATION INCLUDING ADHESIVE STEM CELLS, PRODUCTION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION | June 2020 | September 2024 | Allow | 51 | 1 | 1 | Yes | No |
| 16894569 | GENERATION OF FUNCTIONAL NEUTROPHILS AND MACROPHAGES FROM INDUCED PLURIPOTENT STEM CELLS IN CHEMICALLY DEFINED CONDITIONS USING TRANSIENT EXPRESSION OF ETV2 | June 2020 | May 2025 | Allow | 59 | 3 | 1 | No | No |
| 16568707 | HUMAN HOMOGENEOUS AMNIOTIC FLUID STEM CELL LINES AND USES THEREOF | September 2019 | November 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16479297 | APPARATUS AND METHODS FOR IN VITRO PRECLINICAL HUMAN TRIALS | July 2019 | February 2025 | Allow | 60 | 2 | 1 | No | No |
| 15771781 | METHOD FOR PRODUCING CELL POPULATION COMPRISING MESENCHYMAL STEM CELLS, MESENCHYMAL STEM CELLS, CELL POPULATION, AND PHARMACEUTICAL COMPOSITION | April 2018 | January 2025 | Abandon | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RAHMAN, MASUDUR.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RAHMAN, MASUDUR works in Art Unit 1633 and has examined 53 patent applications in our dataset. With an allowance rate of 67.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 51 months.
Examiner RAHMAN, MASUDUR's allowance rate of 67.9% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by RAHMAN, MASUDUR receive 2.11 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by RAHMAN, MASUDUR is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +32.8% benefit to allowance rate for applications examined by RAHMAN, MASUDUR. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 58% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 27.3% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 27.8% of allowed cases (in the 95% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.